Organization
Janssen Research & Development, LLC, Spring House, PA, United States of America
3 abstracts
Abstract
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP CLINICAL TRIAL OF NIPOCALIMAB IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (SPIREA): STUDY DESIGNOrg: Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, United States of America, Medicine and Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States of America, Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, Janssen Research & Development, LLC, Spring House, PA, United States of America, Janssen Pharmaceutica, Vilvoorde, Belgium,
Abstract
ANXIETY AND DEPRESSION AMONG RHEUMATOID ARTHRITIS PATIENTS, AND ASSOCIATION WITH CLINICAL MEASUREMENTS AND PATIENT REPORTED DISABILITY AND TREATMENT SATISFACTION Org: Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, Janssen Research & Development, LLC, Spring House, PA, United States of America, Adelphi Real World, Bollington, United Kingdom,
Abstract
ASSOCIATION OF BASELINE CYTOTOXIC GENE EXPRESSION WITH USTEKINUMAB RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Janssen Research & Development, LLC, Spring House, PA, United States of America, AMPEL BioSolutions, LLC, Charlottesville, VA, United States of America, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, University of California, Los Angeles, Los Angeles, CA, United States of America, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America,